Abstract

Background:Several biologics available for the treatment of psoriatic arthritis (PsA) have demonstrated effectiveness. A major aim of the treating physician is to find the safest treatment for his patients.Objectives:In this...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB0763 Ustekinumab for the treatment of psoriatic arthritis – results of the first interim analysis of the non-interventional study sustain
F Behrens ... I Schwarze
Annals of the Rheumatic Diseases | VOL. 76
F Behrens, et. al.F Behrens ... I Schwarze
01 Jun 2017
Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
Karen Ly ... Mary Patricia Smith
JAAD Case Reports | VOL. 5
Karen Ly, et. al.Karen Ly ... Mary Patricia Smith
01 Oct 2019
POS1033 SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS OF 4 CLINICAL TRIALS
A Deodhar ... A Kronbergs
-
A Deodhar, et. al.A Deodhar ... A Kronbergs
19 May 2021
Results of direct comparison of the clinical efficacy of ixekizumab and adalimumab: data from the SPIRIT H2H study
T V Korotaeva
Modern Rheumatology Journal | VOL. 14
T V KorotaevaT V Korotaeva
21 Sep 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers